Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:ABUS

Arbutus Biopharma Q2 2025 Earnings Results & Report

Arbutus Biopharma logo
$4.19 +0.08 (+1.95%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$4.22 +0.03 (+0.67%)
As of 10/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arbutus Biopharma beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of $0.01 versus the -$0.02 consensus estimate, while revenue of $10.74 million topped the $2.21 million estimate by $8.53 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Arbutus Biopharma EPS Results

Actual EPS
$0.01
Consensus EPS
-$0.02
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Arbutus Biopharma Revenue Results

Actual Revenue
$10.74 million
Expected Revenue
$2.21 million
Beat/Miss
Beat by +$8.53 million
YoY Revenue Growth
N/A

Upcoming Earnings

Arbutus Biopharma's Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Arbutus Biopharma's Q2 2025 Press ReleasePress Release
(8-K)
Arbutus Biopharma's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Arbutus Biopharma Q2 2025 Earnings FAQ

Arbutus Biopharma (NASDAQ:ABUS) reported earnings of $0.01 per share for Q2 2025, beating the consensus estimate of -$0.02. The report was announced on Wednesday, August 6, 2025.

Arbutus Biopharma reported revenue of $10.74 million for Q2 2025, against a consensus estimate of $2.21 million.

Arbutus Biopharma's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Arbutus Biopharma on the company's earnings history page.

Arbutus Biopharma Earnings Headlines

Arbutus Biopharma (NASDAQ:ABUS) & Syndax Pharmaceuticals (NASDAQ:SNDX) Head-To-Head Comparison
October 13 at 5:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114270
Contrasting Arbutus Biopharma (NASDAQ:ABUS) & Evaxion A/S (NASDAQ:EVAX)
October 13 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114056
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952856-arbutus-biopharma-230m-buyback-and-moderna-cash-de-risk-the-path-to-a-potential-hbv-cure
Arbutus Announces Final Results of Its US$230 Million Modified 'Dutch Auction' Tender Offer
October 2, 2026  |  marketscreener.comM
Tranche Update on Arbutus Biopharma Corporation's Equity Buyback Plan announced on August 21, 2026.
October 1, 2026  |  marketscreener.comM
See More Arbutus Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email.

About Arbutus Biopharma

Arbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection and other viral diseases. The company’s research programs are based primarily on RNA interference (RNAi) therapeutics and small-molecule compounds designed to suppress viral replication and address the underlying biology of persistent infection.

Arbutus’ HBV pipeline has included AB-729, an investigational subcutaneously administered RNAi therapeutic intended to reduce hepatitis B surface antigen, and AB-836, an investigational oral capsid inhibitor designed to interfere with HBV replication. The company also develops and licenses lipid nanoparticle delivery technology, which is intended to help transport nucleic acid medicines into cells.

The company traces its history to Tekmira Pharmaceuticals, which combined with OnCore Biopharma in 2015 and adopted the Arbutus Biopharma name. Arbutus is headquartered in Warminster, Pennsylvania, and conducts research and clinical development through collaborations and studies involving international markets. Its leadership and development strategy have centered on advancing targeted therapies for chronic viral infections while leveraging its expertise in RNA medicines and drug-delivery technologies.

View Arbutus Biopharma Profile
Earnings Tools